Skip to main content

Table 2 Sociodemographic, economic, and clinical characteristics of patients upon admission to the study

From: Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and immune response of HIV patients on antiretroviral therapy: a single-blind randomized control trial

Variables

Moringa group Median (min–max)

Control group Median (min–max)

P

Gender

Male

 

24

 

23

0.99

Female

 

76

 

77

 

Age (years)

49.5 (21–64)

 

47.0 (18–61)

 

0.45

18–49

 

50

 

70

0.78

50–64

 

50

 

30

 

Marital status

Married

 

33

 

30

0.11

Others

 

67

 

70

 

Living Environment

At home

 

47

 

67

0.12

With third party

 

53

 

33

 

Household size

No children

 

10

 

13

0.91

≤3 children

 

43

 

43

 

≥4 children

 

47

 

43

 

Educational level

Low

 

60

 

80

0.09

High

 

40

 

20

 

Professional activity

Not engaged

 

37

 

43

0.59

Engaged

 

63

 

57

 

Anthropometric parameters

Height (cm)

164.0 (6.0)

 

163.1 (7.9)

 

0.55

Weight (kg)

59.6 (12.9)

 

56.9 (10.8)

 

0.29

BMI (kg/m2)

21.8 4.2)

 

21.4 (3.8)

 

0.99

<18.5

 

23

 

20

0.75

≥18.5

 

77

 

80

 

WHO Clinical staging

Stage 2

 

17

 

27

0.34

Stage 3 & 4

 

83

 

73

 

Duration of ART (years)

4.5 (1–8)

 

5.5 (0–14)

 

0.49

<5

 

70

 

50

0.11

≥5

 

30

 

50

 

ART regimen*

AZT + 3TC + NVP

 

80

 

63

0.32

TDF + 3TC+ LPV/r

 

17

 

33

 

ABC + DDI + LPV/r

 

3

 

3

 
  1. ART antiretroviral therapy, AZT Zidovudine, 3TC Lamivudine; NVP, Nevirapine, TDF, Tenofovir; LPV/r Lopinavir +Ritonavir, ABC Abacavir, DDI, Didanosine
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us